EGFR and non-small cell lung carcinoma: A phase II clinical trial NCT04358562 aims to evaluate the efficacy and safety of gefitinib combined with anlotinib, a domestic oral small molecule inhibitor of multi-receptor tyrosine kinase, versus gefitinib alone in advanced non-squamous NSCLC patients whose EGFR mutation was not cleared in plasma ctDNA after 8 weeks of gefitinib first-line treatment, to provide a clinical basis for a new and tolerable treatment that can prolong survival of patients with advanced NSCLC (Table 1).